Sanofi Aventis: New Real Life Studies Illustrate Greater A1C Lowering and Cost Benefit Observed With LANTUS(R) Over Detemir and NPH Insulin

08.09.2008 13:40:06
sanofi-aventis Group: Paris (ots/PRNewswire) - - The THIN, ROLE and LIVE-DE Studies Used Medical Databases or Medical Records to Compare the Benefits of Different Insulin Treatments in Thousands of People Living With Type 2 Diabetes - Abstracts ...

Lesen Sie hier weiter... | Drucken | PDF

Sanofi Aventis: People With Type 2 Diabetes Treated With LANTUS(R) and APIDRA(R) Achieved Greater Reductions in A1C Than Those Treated With Pre-mixed Insulin
Sanofi Aventis : New Study Results Support the"Basal Plus" Strategy With LANTUS(R) and APIDRA(R) to Improve Blood Sugar Control in Patients With Type 2 Diabetes
Sanofi-aventis is Complying With the EMEA's Recommendation to Temporarily Suspend the Marketing Authorisation of Acomplia(R) in Obese and Overweight Patients
Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile
RecordAF Registry Will Provide First Global Insight Into Real Life Management of Atrial Fibrillation - A Major Cause of Cardiovascular Death and Hospitalization
Bimatoprost / Timolol Fixed Combination Therapy Demonstrates Significantly Better IOP Control Over 12 Hours Compared to Latanoprost / Timolol Combination
Russia Chooses Inactivated Polio Vaccine from Sanofi Pasteur for Primary Immunization of all Infants
Meilensteinstudie ATHENA mit Multaq(R) (Dronedaron) zeigt 24 Prozent Reduktion für kardiovaskuläre Hospitalisierung oder Tod bei Patienten mit Vorhofflimmern
Landmark ATHENA Study Findings With Multaq(R)(dronedarone) Show 24% Reduction in Cardiovascular Hospitalisation or Death in Patients With Atrial Fibrillation
Wichtige Schritte im Kampf gegen Vorhofflimmern und der damit verbundenen kardiovaskulären Risiken